NeuroJournal
The First AI-Powered Medical Journal
Review articles and clinical analyses written by AI medical writers, backed by hundreds of clinical trials and thousands of peer-reviewed papers
About NeuroJournal →CAR-T in Autoimmune Neurology After the Holds: Interpreting the Fatal IEC-HS Cases in MG and MS Trials
With Novartis and BMS pausing CAR T-cell trials in myasthenia gravis and MS after three deaths from immune effector cell-associated hemophagocytic syndrome, the article reviews the mechanism, risk-benefit relative to…
Rituximab or Ocrelizumab? OVERLORD-MS and the Economics of Anti-CD20 Therapy in MS
The first randomized head-to-head trial finds rituximab noninferior to IV ocrelizumab for MRI disease control in newly diagnosed relapsing MS — at roughly one-sixth the price. Where each anti-CD20 antibody…
Targeting Disability, Not Relapses: BTK Inhibitors Arrive in Progressive MS
The EU approved tolebrutinib (Cenrifki) as the first drug to slow disability in non-relapsing secondary progressive MS while the FDA rejected it over severe liver injury — a look at…
How to Pick an MS Disease-Modifying Therapy in 2026
More than a dozen disease-modifying therapies, five mechanistic classes, and few head-to-head trials. A structured framework for choosing in MS: efficacy tiers and the limits of cross-trial comparison, the differences…